In order to mass produce a treatment for the current global pandemic, pharmaceutical manufacturers need to stretch their capacity to its fullest. Could production planning and scheduling be the key that unlocks improved throughput and maximised yield?
The numbers reflecting the rapid global spread of Coronavirus (Covid-19) are devastating. Almost 1.9 million cases have been confirmed in 176 countries with more than 119,000 deaths, according to the latest WHO statistics (as of 15 April, 2020). In the face of such a global crisis, pharmaceutical manufacturers are experiencing mounting pressure to produce treatments…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
